Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Skin and Connective Tissue Diseases

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Breast Neoplasms

Inflammatory Breast Neoplasms

Castleman Disease

Breast Diseases

Skin Diseases

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Lymphatic Diseases

Inflammatory Breast Cancer

Unicentric Castleman Disease

CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.

CX-4945 oral formulation

Clinical Trials Office Mayo Clinic Cancer Center

Donald Northfelt, MD

P. Zeller

Robert F Marschke, MD

Pat Zeller

R. McFarland, MD

R. Alvarez, MD

Study Director

This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability and highest safe dose level of this CK2 inhibitor in patients with advanced solid tumor cancers, Castleman's Disease or Multiple Myeloma.

Elevated CK2 activity has been associated with malignant transformation and aggressive tumor growth and overexpression of CK2 has been documented in multiple types of cancer. CK2 has emerged as a potential anticancer target and inhibition of CK2 represents a potential therapeutic strategy to target a specific molecular defect perpetuating many cancers. CX-4945 has demonstrated potent inhibition of CK2 enzymatic activity. This study will evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects of CX-4945 administered to patients with malignancies or lymphoproliferative disorders known to overexpress CK2 including advanced solid tumors, Multiple Myeloma and Castleman's Disease.

Dose-escalation Study of Oral CX-4945

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma

Cylene Pharmaceuticals

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Dose-escalation Study of Oral CX-4945	NCT00891280	Advanced Solid ... Breast Cancer Inflammatory Br... Castleman's Dis... Multiple Myelom...	CX-4945 oral fo...	18 Years -	Cylene Pharmaceuticals
Dose-escalation Study of Oral CX-4945	NCT00891280	Advanced Solid ... Breast Cancer Inflammatory Br... Castleman's Dis... Multiple Myelom...	CX-4945 oral fo...	18 Years -	Cylene Pharmaceuticals

Spots Global Cancer Trial Database for ck2 inhibitor